Issue 01

REGULATION AND LEGISLATION


Oregon psilocybin decriminalisation campaign says it will qualify for the November ballot.


DC activists submit signatures to put decriminalisation campaign on the November ballot.


New Medical Psychedelics Working Group to lobby for ease in UK research restrictions.


Veteran’s commission pushes for increased research into cannabis and psychedelics.

BUSINESS AND INVESTMENT


British psychedelics firm Beckley Psytech raises US$3.7 million in Series A funding.


Professor David Nutt joins AWAKN Life Sciences.


Empower Clinics begins search for Dosed Wellness clinic site in Vancouver.


Former Pfizer, Yale drug discovery expert joins Mydecine Innovations’ advisory board.


New psychedelics firms, Psilera Bioscience and CannaGlobal Wellness, enter the market.


Numinus Wellness announces the launch of a clinical advisory council.


ATAI is utilising digital tools to improve psychedelic therapies and monitor patients.


Mota Ventures appoints Roger C. Clinton to advisory board of new acquisition, Verrian.


Field Trip’s first facility reopens and establishes ‘Basecamp’ mental wellness program for veterans.

RESEARCH AND SCIENCE


Kruzo Inc. and Rangsit University agree to establish a Psychedelic Research Institute.


Mindbloom to begin offering remote-enabled psychedelic therapy sessions in California.


Revive Therapeutics submits FDA application to begin Phase 3 trials for COVID-19 drug.


BC-based Havn Life Sciences launches to develop psilocybin products for research.


Columbus Community Hospital reduces opioids needed in surgery by using ketamine.

THE PSYCHEDELICS AS MEDICINE REPORT

Medical psychedelics are experiencing a renaissance, pushing forward the frontiers of healthcare innovation.
PSYCH: The Psychedelics as Medicine Report provides unparalleled insights and intelligence from industry experts and market leaders, helping to guide investors, operators and regulators through this transient phase.

FEATURED ARTICLE

PSYCH Symposium at Prohibition Partners LIVE brought together world-class speakers, industry giants and pioneering investors, to discuss psychedelics and their potential to disrupt how we treat mental health. Read the highlights.